What is the recommended cyclobenzaprine dosing for a patient with an estimated glomerular filtration rate (eGFR) of 23 mL/min/1.73 m²?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cyclobenzaprine Dosing with eGFR 23 mL/min/1.73 m²

No dose adjustment is required for cyclobenzaprine in patients with renal impairment, including those with an eGFR of 23 mL/min/1.73 m²—use standard dosing of 5 mg three times daily, with potential titration to 10 mg three times daily based on response.

Rationale

Cyclobenzaprine does not require renal dose adjustment because it is primarily metabolized hepatically and excreted as glucuronides via the kidney, not as active drug 1. The FDA labeling provides no specific dosing modifications for renal impairment across all severity levels.

Standard Dosing Approach

  • Initial dose: 5 mg three times daily 1
  • Titration: May increase to 10 mg three times daily based on individual response 1
  • Duration: Limit use to 2-3 weeks 1

Key Pharmacokinetic Considerations

The drug undergoes extensive hepatic metabolism via CYP3A4, 1A2, and 2D6 pathways 1. While metabolites are renally excreted as glucuronides, the FDA labeling explicitly addresses hepatic impairment (requiring dose reduction) but makes no mention of renal impairment requiring adjustment 1.

Important Caveats

When to Consider Lower Dosing

Reduce dosing frequency or use lower doses (5 mg) in:

  • Elderly patients (≥65 years): Plasma concentrations are 1.7-fold higher, with elderly males showing 2.4-fold increases 1
  • Hepatic impairment: AUC and Cmax approximately double even in mild impairment; start with 5 mg and titrate slowly 1

Clinical Monitoring

With eGFR 23 mL/min/1.73 m², monitor for:

  • Sedation and anticholinergic effects: These may be more pronounced due to potential accumulation of glucuronide metabolites
  • Drug interactions: Particularly with other CNS depressants
  • Cardiovascular effects: Cyclobenzaprine can cause slight to moderate heart rate increases 1

Common Pitfall

Do not confuse the need for hepatic dose adjustment with renal adjustment. The effective half-life of 18 hours (range 8-37 hours) and slow elimination are related to hepatic metabolism, not renal clearance 1. The absence of renal dosing recommendations in FDA labeling is intentional and evidence-based.

References

Related Questions

Should an 88-year-old patient with an estimated glomerular filtration rate of 85 mL/min/1.73 m² take meloxicam (Melodic)?
Is it appropriate to prescribe phentermine 37.5 mg capsule to a 59‑year‑old female patient with an estimated glomerular filtration rate of 64.9 mL/min/1.73 m²?
What dosing adjustments are needed for a 57-year-old male with an estimated glomerular filtration rate of 100 mL/min?
Can I resume sertraline 50 mg with an estimated glomerular filtration rate of 43 mL/min/1.73 m²?
In an 88-year-old patient with an estimated glomerular filtration rate of 28 mL/min/1.73 m² who is taking omeprazole 20 mg daily, does the medication require renal dose adjustment?
What is the appropriate management for a pediatric patient presenting with vomiting and diarrhea?
How should low-dose lithium be started, what monitoring is required, and what are its contraindications and alternative mood stabilizers?
What is the likely diagnosis and appropriate treatment for a child with a 10‑14‑day pruritic rash involving the arms, face, neck, scalp, and diaper/underwear line?
Is hypothyroidism associated with nighttime awakenings and poor sleep?
In a woman with irregular menses (oligo/anovulation) and facial hirsutism but no signs of virilism, should we initiate therapy without further investigation or first screen for polycystic ovary syndrome (PCOS) and serum testosterone level?
In a 43-year-old man with iron‑deficiency anemia, should he undergo colonoscopy, esophagogastroduodenoscopy (EGD), or both?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.